Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (20 quarters reported)
$187M in Q4 2021 → $1.81B now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Legend Biotech Corp | 10.1% | Added 205% | 9,154,389 | $182M |
| CT Celldex Therapeutics Inc New | 9.1% | Trimmed 4.8% | 5,066,051 | $164M |
| Syndax Pharmaceuticals Inc | 8.5% | Added 1.2% | 8,150,959 | $153M |
| Vaxcyte Inc | 8.2% | Trimmed 11% | 2,607,964 | $148M |
| VT Viridian Therapeutics Inc | 7.0% | Trimmed 4.7% | 6,148,000 | $127M |
| Cogent Biosciences Inc | 6.7% | Added 3.4% | 3,792,289 | $121M |
| Travere Therapeutics Inc | 6.5% | Unchanged | 2,000,000 | $118M |
| Urogen Pharma Ltd | 5.5% | Unchanged | 2,434,207 | $98.9M |
| VT Vera Therapeutics Inc | 5.4% | Added 3.8% | 3,000,000 | $96.9M |
| Beam Therapeutics Inc | 5.3% | Added 38% | 3,933,894 | $96.2M |
| Cytomx Therapeutics Inc. | 3.2% | Trimmed 2.6% | 21,140,726 | $57.5M |
| Mbx Biosciences Inc | 3.0% | Unchanged | 934,799 | $54.8M |
| Summit Therapeutics Inc | 2.8% | Added 150% | 3,000,000 | $50.7M |
| Relay Therapeutics Inc | 2.7% | Trimmed 17% | 2,751,500 | $49.7M |
| Cullinan Therapeutics Inc | 2.6% | Unchanged | 3,114,132 | $47.8M |
| IH Immunocore Hldgs PLC | 2.3% | Unchanged | 1,375,000 | $41.6M |
| Nurix Therapeutics Inc | 1.6% | Unchanged | 1,194,757 | $28.3M |
| Pharvaris N V | 1.4% | Added 25% | 824,843 | $26.2M |
| Burning Rock Biotech Ltd | 1.2% | Unchanged | 1,238,563 | $21.8M |
| Biocryst Pharmaceuticals Inc | 1.2% | Unchanged | 2,522,660 | $21M |
| Surrozen Inc | 0.9% | New | 486,252 | $15.6M |
| Sutro Biopharma Inc | 0.8% | Unchanged | 872,558 | $14.1M |
| Xenon Pharmaceuticals Inc | 0.6% | New | 280,000 | $10.4M |
| Evommune Inc | 0.5% | New | 1,200,000 | $9.91M |
| Prelude Therapeutics Inc | 0.5% | Trimmed 4.3% | 2,311,955 | $9.04M |
| Geron Corp | 0.5% | Unchanged | 6,836,318 | $8.41M |
| PM Parabilis Medicines Inc | 0.4% | Unchanged | 250,000 | $8.07M |
| Alector Inc | 0.4% | Added 13% | 4,308,494 | $7.97M |
| AP Amarin Corp PLC | 0.4% | Unchanged | 532,982 | $6.93M |
| Harrow Inc | 0.2% | New | 124,655 | $3.84M |
| Caribou Biosciences Inc | 0.2% | Unchanged | 2,503,302 | $3.18M |
| PT Proqr Thrapeutics N V | 0.1% | Unchanged | 1,566,317 | $2.6M |
| Engene Therapeutics Inc | 0.1% | Unchanged | 457,855 | $916K |
| Traws Pharma Inc | 0.0% | Unchanged | 84,400 | $50.1K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Legend Biotech Corp | Added | +6,153,184 | +$122M | 10.1% |
| Summit Therapeutics Inc | Added | +1,800,000 | +$30.4M | 2.8% |
| Beam Therapeutics Inc | Added | +1,093,102 | +$26.7M | 5.3% |
| Vaxcyte Inc | Trimmed | −314,371 | −$17.9M | 8.2% |
| Surrozen Inc | New | +486,252 | +$15.6M | 0.9% |
| Insmed Inc | Exited | −100,000 | −$10.7M | — |
| Xenon Pharmaceuticals Inc | New | +280,000 | +$10.4M | 0.6% |
| Evommune Inc | New | +1,200,000 | +$9.91M | 0.5% |
| Relay Therapeutics Inc | Trimmed | −548,500 | −$9.9M | 2.7% |
| CT Celldex Therapeutics Inc New | Trimmed | −256,857 | −$8.32M | 9.1% |
Showing the 10 largest of 20 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| VT Viridian Therapeutics Inc | Added | +4,112,225 | +$75.5M | 6.6% |
| Legend Biotech Corp | Added | +1,424,910 | +$41.2M | 4.8% |
| Kalvista Pharmaceuticals Inc | Exited | −1,820,954 | −$36.7M | — |
| Relay Therapeutics Inc | Added | +1,875,741 | +$35.1M | 3.4% |
| Apellis Pharmaceuticals Inc | Exited | −825,000 | −$33.2M | — |
| Biocryst Pharmaceuticals Inc | Trimmed | −3,158,135 | −$31.6M | 1.4% |
| Beam Therapeutics Inc | Trimmed | −841,393 | −$28.9M | 5.4% |
| Cytomx Therapeutics Inc. | Added | +6,690,000 | +$25.1M | 4.5% |
| Travere Therapeutics Inc | Added | +430,982 | +$24.5M | 6.3% |
| Travere Therapeutics Inc | Exited | −800,000 | −$23.8M | — |
Showing the 10 largest of 35 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cogent Biosciences Inc | Trimmed | −2,127,892 | −$81.9M | 9.6% |
| Tyra Biosciences Inc | Exited | −1,564,492 | −$41.1M | — |
| Urogen Pharma Ltd | New | +2,247,393 | +$40.4M | 2.5% |
| Cg Oncology Inc | Exited | −945,830 | −$39.3M | — |
| Biocryst Pharmaceuticals Inc | Trimmed | −3,685,731 | −$35.1M | 3.3% |
| Travere Therapeutics Inc | Added | +1,051,134 | +$31.2M | 2.9% |
| Beam Therapeutics Inc | Added | +1,241,971 | +$29.6M | 5.4% |
| Legend Biotech Corp | New | +1,576,295 | +$28.5M | 1.8% |
| Cytomx Therapeutics Inc. | Added | +6,047,016 | +$28.4M | 4.4% |
| Beam Therapeutics Inc | Exited | −937,000 | −$26M | — |
Showing the 10 largest of 33 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| VT Viridian Therapeutics Inc | Trimmed | −2,957,386 | −$92M | 2.9% |
| Cogent Biosciences Inc | Trimmed | −1,720,949 | −$61.1M | 14.0% |
| Cg Oncology Inc | Trimmed | −1,059,375 | −$44M | 2.5% |
| Wave Life Sciences Ltd | Trimmed | −2,390,948 | −$40.6M | 2.4% |
| Mbx Biosciences Inc | Trimmed | −1,065,201 | −$33.6M | 1.9% |
| Engene Holdings Inc | Trimmed | −3,501,192 | −$31.6M | 0.9% |
| VT Vera Therapeutics Inc | Trimmed | −594,749 | −$30.1M | 11.1% |
| Beam Therapeutics Inc | New | +937,000 | +$26M | 1.7% |
| Cytomx Therapeutics Inc | Added | +5,319,574 | +$22.7M | 2.4% |
| Tyra Biosciences Inc | Trimmed | −765,506 | −$20.1M | 2.6% |
Showing the 10 largest of 39 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mbx Biosciences Inc | New | +2,000,000 | +$35M | 2.6% |
| UT United Therapeutics Corp Del | New | +67,588 | +$20M | 1.5% |
| Apellis Pharmaceuticals Inc | New | +808,607 | +$18.3M | 1.4% |
| Cg Oncology Inc | Trimmed | −452,462 | −$18.2M | 6.0% |
| VT Vera Therapeutics Inc | Added | +600,913 | +$17.5M | 8.7% |
| Pharvaris N V | New | +675,000 | +$16.8M | 1.3% |
| Travere Therapeutics Inc | Trimmed | −590,964 | −$14.1M | 1.7% |
| Nurix Therapeutics Inc | Added | +995,000 | +$9.19M | 1.5% |
| Urogen Pharma Ltd | Trimmed | −374,161 | −$9.19M | 0.5% |
| Cogent Biosciences Inc | Trimmed | −606,385 | −$8.71M | 8.4% |
Showing the 10 largest of 17 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Natera Inc | Exited | −1,167,570 | −$165M | — |
| VT Vera Therapeutics Inc | Added | +1,026,887 | +$24.2M | 8.7% |
| IH Immunocore Hldgs PLC | Trimmed | −719,309 | −$22.6M | 3.3% |
| Soleno Therapeutics Inc | Exited | −302,500 | −$21.6M | — |
| Legend Biotech Corp | Exited | −610,000 | −$20.7M | — |
| AP Amarin Corp PLC | New | +576,111 | +$9.34M | 1.0% |
| Urogen Pharma Ltd | Added | +631,573 | +$8.65M | 1.0% |
| CT Celldex Therapeutics Inc New | Trimmed | −399,271 | −$8.13M | 13.4% |
| AP Amarin Corp PLC | Exited | −12,414,628 | −$5.56M | — |
| Liquidia Corporation | Trimmed | −433,755 | −$5.4M | 0.3% |
Showing the 10 largest of 32 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | Exited | −300,000 | −$176M | — |
| Natera Inc | Trimmed | −854,528 | −$121M | 13.9% |
| Dynavax Technologies Corp | Trimmed | −3,940,038 | −$51.1M | 2.9% |
| Vaxcyte Inc | Added | +863,204 | +$32.6M | 10.2% |
| CT Celldex Therapeutics Inc New | Added | +1,435,793 | +$26.1M | 9.9% |
| Liquidia Corporation | Trimmed | −1,632,526 | −$24.1M | 0.8% |
| VT Vera Therapeutics Inc | Added | +942,090 | +$22.6M | 4.8% |
| Soleno Therapeutics Inc | New | +302,500 | +$21.6M | 1.8% |
| Legend Biotech Corp | New | +610,000 | +$20.7M | 1.7% |
| VT Viridian Therapeutics Inc | Added | +1,373,738 | +$18.5M | 5.3% |
Showing the 10 largest of 28 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | New | +300,000 | +$176M | 10.4% |
| Vaxcyte Inc | Added | +1,297,508 | +$106M | 11.3% |
| CT Celldex Therapeutics Inc New | Added | +1,605,598 | +$40.6M | 7.6% |
| IH Immunocore Hldgs PLC | New | +1,225,576 | +$36.2M | 2.1% |
| Syndax Pharmaceuticals Inc | Added | +2,677,075 | +$35.4M | 6.7% |
| Dynavax Technologies Corp | Trimmed | −1,771,852 | −$22.6M | 5.0% |
| Engene Holdings Inc | Added | +3,257,863 | +$21.7M | 2.0% |
| Cg Oncology Inc | Added | +748,900 | +$21.5M | 4.3% |
| VT Viridian Therapeutics Inc | Added | +814,967 | +$15.6M | 3.8% |
| Cullinan Therapeutics Inc | New | +1,252,738 | +$15.3M | 0.9% |
Showing the 10 largest of 25 changes.
Loading...